Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Warner-Lambert Savings Would Be Akin To Acquiring Another Zoloft

Executive Summary

A Pfizer/Warner-Lambert combination would achieve $1.6 bil. in cost savings by 2002, Pfizer declared.

You may also be interested in...



AHP Sale Of Cyanamid To BASF Will Re-Open Merger Possibilities

The sale of American Home Products' agricultural and crop sciences division Cyanamid will give the company a pharmaceutical profile that clears the way for a new round of merger discussions.

AHP Sale Of Cyanamid To BASF Will Re-Open Merger Possibilities

The sale of American Home Products' agricultural and crop sciences division Cyanamid will give the company a pharmaceutical profile that clears the way for a new round of merger discussions.

Pfizer Lipitor Profitability Among Items In Dispute In Warner-Lambert Bid

The effect of the Lipitor co-promotion on Pfizer's earnings ranges from break-even to one quarter of profits, depending on which partner in the agreement is doing the accounting.

Related Content

UsernamePublicRestriction

Register

PS035605

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel